Natera (NTRA) announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology, ESMO, Congress, taking place October 17-21 in Berlin, Germany. The slate includes six oral presentations. The IMvigor011 trial, sponsored by Genentech, a member of the Roche Group, has been selected for a Presidential Symposium on October 20. The IMvigor011 trial, sponsored by Genentech, a member of the Roche Group (RHHBY), has been selected for a Presidential Symposium on October 20. Additional oral presentations include results from the SunRISe-4 trial in MIBC, the INTERCEPT trial in colorectal cancer, and Natera’s early cancer detection program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera enrolls over 1,600 patients in EXPAND trial
- Natera announces publication of Signatera validation study
- Humana initiated, Paycom upgraded: Wall Street’s top analyst calls
- Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency Concerns
- Natera initiated with an Equal Weight at Wells Fargo